Blog
RSS FeedPosted by Michael Wonder on 30 Apr 2024
New Zealand Pharmaceutical Schedule - 1 May 2024
1 May 2024 - The May 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Apr 2024
Schedule of Pharmaceutical Benefits - 1 May 2024
1 May 2024 - The May 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Apr 2024
Gefapixant for the treatment of patients with refractory or unexplained chronic cough
30 April 2024 - NICE is unable to make a recommendation on the use of gefapixant (Lyfnua) for the treatment of ...
Posted by Michael Wonder on 30 Apr 2024
Oh, Canada: US patients don't want your health policies
29 April 2024 - There's never been a worse time to get sick in Canada. Our northern neighbors must wait ...
Posted by Michael Wonder on 29 Apr 2024
Government boosts PHARMAC funding by $1.7 billion as inaugural medicines summit begins
29 April 2024 - The Government will boost PHARMAC’s budget by more than $1.7 billion over the next four years, ...
Posted by Michael Wonder on 29 Apr 2024
Idebenone for the treatment of patients 12 years and older with visual impairment associated with Leber’s hereditary optic neuropathy
24 April 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Apr 2024
Life prolonging breast cancer drug recommended for PBS subsidy, but it is not time to celebrate
26 April 2024 - Breast Cancer Network Australia (BCNA) today welcomed a decision by the PBAC to recommend the life ...
Posted by Michael Wonder on 28 Apr 2024
Former Deputy Prime Minister Paula Bennett appointed new chair of PHARMAC
28 April 2024 - Former Deputy Prime Minister Paula Bennett has been appointed the new chair of the national drug ...
Posted by Michael Wonder on 27 Apr 2024
New hope for Aussies battling early stage breast cancer
28 April 2024 - For the first time in 15 years women with an invasive form of early breast cancer ...
Posted by Michael Wonder on 26 Apr 2024
Recommendations made by the PBAC (March 2024)
26 April 2024 - Recommendations made by the PBAC in March 2024 relating to the listing of medicines on the PBS ...
Posted by Michael Wonder on 26 Apr 2024
Melphalan flufenamide hydrochloride in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
25 April 2024 - NICE is unable to make a recommendation on the use of melphalan flufenamide hydrochloride (Pepaxti) in combination ...
Posted by Michael Wonder on 25 Apr 2024
Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment
24 April 2024 - A new targeted drug combination treatment, described as a ‘step-change in care’ for children and young ...
Posted by Michael Wonder on 24 Apr 2024
Pembrolizumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with advanced biliary tract cancer
24 April 2024 - NICE is unable to make a recommendation on the use of pembrolizumab (Keytruda) in combination with cisplatin ...
Posted by Michael Wonder on 23 Apr 2024
More treatment options proposed for people with multiple myeloma and myelodysplastic syndrome
23 April 2024 - PHARMAC is proposing to fund more treatments for people with a type of blood cancer, multiple ...
Posted by Michael Wonder on 22 Apr 2024
Boost for pharmacists for flu season
20 April 2024 - The Albanese Government is protecting Australians in aged care and disability homes by funding pharmacists for the ...